Last edition
News about Clinical Trials
Funds of $130m raised for B cell medications
Be Bio raises $130m to foster designed B cell medications. As a feature of the financing, ARCH Venture Partners overseeing chief Steven Gillis will join Be Bio's governing body.
Clinical Trials | 23/04/2022 | By Sudeep Soparkar | 697
BioXcel to develop drugs in oncology
BioXcel shapes entirely claimed auxiliary OnkosXcel to foster prescriptions centered in oncology
Clinical Trials | 21/04/2022 | By Sudeep Soparkar | 825
IDB therapies to improve with lymphoid cell maturity
New knowledge on lymphoid cell maturity could lead to more effective IBD therapies
Clinical Trials | 18/04/2022 | By Sudeep Soparkar | 637
Effects of rilzabrutinib in individuals with insusceptible thrombocytopenia
Positive phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
Clinical Trials | 16/04/2022 | By Sudeep Soparkar | 1082
Cryo-electron microscopy answers for help underlying science research
Thermo Fisher Scientific, the world innovator in serving science, as of late sent the cutting edge cryo-transmission electron magnifying lens at the Center for Cellular and Molecular Biology (CCMB), Hyderabad, Telangana. The office was inaugurated by Dr Shekhar Mande, chief general, Council of Scientific and Industrial Research (CSIR).
Clinical Trials | 13/04/2022 | By Sudeep Soparkar | 691
New Toolkit Supports Digital Endpoints in Drug Development
DiMe, Biogen, Eli Lilly, Pfizer, and other top pharma companies launched a toolkit to ensure that organizations develop digital endpoint evidence in an acceptable way during drug development.
Clinical Trials | 12/04/2022 | By Sudeep Soparkar | 625
The GTAEC is an independent body of experts representing diverse areas of biomedical research, concerned government agencies and other stakeholders constituted and notified by the department of health research, Union ministry of health and family welfare to oversee the activities in the field of gene therapy research in India
Clinical Trials | 17/02/2022 | By Darshana | 799
In the past 12 months, Velocity has randomized 25,000 patients into phase II and III studies in the US. The tech investments will enable Velocity to be more efficient in managing studies, identifying patients for studies, and increasing the frequency of participation in studies
Clinical Trials | 16/02/2022 | By Darshana | 684
Drug Technical Advisory Board suggests recommendations under clinical trial to DCGI
DTAB has recommended that the proposed provisions for grant of licence to manufacture and stock of new drug which is under clinical trial is considered appropriate for drugs/vaccines being developed for emergency/life-saving/COVID-19 and similar such conditions of public health importance
Clinical Trials | 14/02/2022 | By Darshana | 882
Serum's proposal to manufacture vaccine against omicron for test and analysis, gets a DGCI nod
The Drugs Controller General of India (DCGI) has approved Serum Institute of India?s proposal to manufacture a vaccine against omicron variant of coronavirus for examination, test and analysis.
Clinical Trials | 09/02/2022 | By Darshana | 215
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy